[go: up one dir, main page]

WO1999041368A3 - Optimization of immunomodulatory properties of genetic vaccines - Google Patents

Optimization of immunomodulatory properties of genetic vaccines Download PDF

Info

Publication number
WO1999041368A3
WO1999041368A3 PCT/US1999/003020 US9903020W WO9941368A3 WO 1999041368 A3 WO1999041368 A3 WO 1999041368A3 US 9903020 W US9903020 W US 9903020W WO 9941368 A3 WO9941368 A3 WO 9941368A3
Authority
WO
WIPO (PCT)
Prior art keywords
optimization
immunomodulatory properties
genetic vaccines
molecules
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/003020
Other languages
French (fr)
Other versions
WO1999041368A2 (en
Inventor
Juha Punnonen
Willem P C Stemmer
Robert Gerald Whalen
Russell Howard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxygen Inc
Original Assignee
Maxygen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Inc filed Critical Maxygen Inc
Priority to MXPA00007889A priority Critical patent/MXPA00007889A/en
Priority to EP99906948A priority patent/EP1053312A2/en
Priority to CA002320960A priority patent/CA2320960A1/en
Priority to JP2000531549A priority patent/JP2002507392A/en
Priority to AU26741/99A priority patent/AU2674199A/en
Publication of WO1999041368A2 publication Critical patent/WO1999041368A2/en
Publication of WO1999041368A3 publication Critical patent/WO1999041368A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

This invention provides methods for obtaining molecules that can modulate an immune response, and immunomodulatory molecules obtained using the methods. The molecules find use, for example, in the tailoring of an immune response induced by a genetic vaccine for a desired purpose.
PCT/US1999/003020 1998-02-11 1999-02-10 Optimization of immunomodulatory properties of genetic vaccines Ceased WO1999041368A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MXPA00007889A MXPA00007889A (en) 1998-02-11 1999-02-10 Optimization of immunomodulatory properties of genetic vaccines.
EP99906948A EP1053312A2 (en) 1998-02-11 1999-02-10 Optimization of immunomodulatory properties of genetic vaccines
CA002320960A CA2320960A1 (en) 1998-02-11 1999-02-10 Optimization of immunomodulatory properties of genetic vaccines
JP2000531549A JP2002507392A (en) 1998-02-11 1999-02-10 Optimization of immunomodulatory properties of gene vaccines
AU26741/99A AU2674199A (en) 1998-02-11 1999-02-10 Optimization of immunomodulatory properties of genetic vaccines

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7429498P 1998-02-11 1998-02-11
US2176998A 1998-02-11 1998-02-11
US09/021,769 1998-02-11
US60/074,294 1998-02-11

Publications (2)

Publication Number Publication Date
WO1999041368A2 WO1999041368A2 (en) 1999-08-19
WO1999041368A3 true WO1999041368A3 (en) 1999-12-16

Family

ID=26695070

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US1999/003022 Ceased WO1999041369A2 (en) 1998-02-11 1999-02-10 Genetic vaccine vector engineering
PCT/US1999/003020 Ceased WO1999041368A2 (en) 1998-02-11 1999-02-10 Optimization of immunomodulatory properties of genetic vaccines
PCT/US1999/003023 Ceased WO1999041402A2 (en) 1998-02-11 1999-02-10 Targeting of genetic vaccine vectors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1999/003022 Ceased WO1999041369A2 (en) 1998-02-11 1999-02-10 Genetic vaccine vector engineering

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US1999/003023 Ceased WO1999041402A2 (en) 1998-02-11 1999-02-10 Targeting of genetic vaccine vectors

Country Status (6)

Country Link
EP (3) EP1053312A2 (en)
JP (3) JP2002503478A (en)
AU (3) AU2674299A (en)
CA (3) CA2320431A1 (en)
MX (3) MXPA00007889A (en)
WO (3) WO1999041369A2 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821957B2 (en) 1997-05-20 2004-11-23 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US7058515B1 (en) 1999-01-19 2006-06-06 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US7153655B2 (en) 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US7262012B2 (en) 2002-05-17 2007-08-28 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populations
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US7462469B2 (en) 2000-01-11 2008-12-09 Maxygen, Inc. Integrated system for diversity generation and screening
US9512382B2 (en) 2009-10-16 2016-12-06 Bunge Global Innovation, Llc Oil degumming methods

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
AU1124499A (en) 1997-10-28 1999-05-17 Maxygen, Inc. Human papillomavirus vectors
EP1030861A4 (en) 1997-10-31 2001-09-05 Maxygen Inc Modification of virus tropism and host range by viral genome shuffling
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
JP2002517995A (en) 1998-06-17 2002-06-25 マキシジェン， インコーポレイテッド Method for producing a polynucleotide having desired properties
WO2000009682A1 (en) 1998-08-12 2000-02-24 Maxygen, Inc. Dna shuffling of monooxygenase genes for production of industrial chemicals
WO2000020573A2 (en) 1998-10-07 2000-04-13 Maxygen, Inc. Dna shuffling to produce nucleic acids for mycotoxin detoxification
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
AU1619400A (en) 1998-11-10 2000-05-29 Maxygen, Inc. Modified adp-glucose pyrophosphorylase for improvement and optimization of plantphenotypes
JP2002537762A (en) 1999-01-05 2002-11-12 トラスティーズ オブ ボストン ユニバーシティ Improved nucleic acid cloning
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
EP1073710A4 (en) * 1999-02-04 2007-12-19 Verenium Corp Non-stochastic generation of genetic vaccines and enzymes
US7384387B1 (en) 1999-02-11 2008-06-10 Maxygen, Inc. High throughput mass spectrometry
US6531316B1 (en) 1999-03-05 2003-03-11 Maxyag, Inc. Encryption of traits using split gene sequences and engineered genetic elements
CN1377406A (en) 1999-07-22 2002-10-30 宝洁公司 Protease conjugates having sterically protected clip sites
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
CA2376045A1 (en) 1999-07-22 2001-02-01 The Procter & Gamble Company Subtilisin protease variants having amino acid substitutions in defined epitope regions
BR0012693A (en) 1999-07-22 2002-04-09 Procter & Gamble Variant, of subtilisin-like protease; cleaning composition; and personal care composition
US6686515B1 (en) 1999-11-23 2004-02-03 Maxygen, Inc. Homologous recombination in plants
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
EP1254212A2 (en) 2000-02-09 2002-11-06 Genvec, Inc. Methods of preparing and using a viral vector library
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
AU2001259957B2 (en) * 2000-05-26 2006-06-15 Savine Therapeutics Pty Ltd Synthetic peptides and uses therefore
WO2002000717A2 (en) 2000-06-23 2002-01-03 Maxygen, Inc. Novel co-stimulatory molecules
AU2001268716A1 (en) 2000-06-23 2002-01-08 Maxygen, Inc. Novel chimeric promoters
WO2002000232A2 (en) * 2000-06-26 2002-01-03 Maxygen, Inc. Methods and compositions for developing spore display systems for medicinal and industrial applications
US6858422B2 (en) 2000-07-13 2005-02-22 Codexis, Inc. Lipase genes
DE10060959A1 (en) * 2000-12-06 2002-06-20 Aventis Res & Tech Gmbh & Co Processes for isolating and identifying effectors
US20020146732A1 (en) * 2001-02-02 2002-10-10 Padgett Hal S. Method of increasing complementarity in a heteroduplex
WO2002094992A2 (en) 2001-05-18 2002-11-28 Rigel Pharmaceuticals, Incorporated Directed evolution of protein in mammalian cells
WO2003008436A2 (en) * 2001-07-19 2003-01-30 Icogen Corporation Methods for the identification of peptidyl compounds interacting with extracellular target molecules
NZ533294A (en) * 2001-11-21 2007-06-29 Univ Leland Stanford Junior Polynucleotide therapy for diabetes associated with self-proteins, -polypeptides and -peptides
SG165155A1 (en) 2002-02-26 2010-10-28 Maxygen Inc Novel flavivirus antigens
DK2278509T3 (en) 2002-03-01 2014-12-15 Codexis Mayflower Holdings Llc Methods, systems and software for identification of functional biomolecules
US7620500B2 (en) 2002-03-09 2009-11-17 Maxygen, Inc. Optimization of crossover points for directed evolution
BRPI0309391B1 (en) 2002-04-19 2018-10-30 Dsm Food Specialties B V vector comprising nucleic acid encoding phospholipase activity polypeptide, transformed cell, protein preparation, preparation method and related methods
US7226771B2 (en) 2002-04-19 2007-06-05 Diversa Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
AU2003304275A1 (en) 2002-08-06 2005-01-21 Pioneer Hi-Bred International, Inc. Ap1 amine oxidase variants
CA2510309C (en) 2002-12-16 2014-09-16 Liyange P. Perera Recombinant vaccine viruses expressing il-15 and methods of using the same
DK2194133T3 (en) 2003-03-06 2016-02-29 Basf Enzymes Llc Amylases, nucleic acids encoding them, and methods of making and using the same
CA2515583C (en) 2003-03-07 2015-07-14 Diversa Corporation Hydrolases, nucleic acids encoding them and methods for making and using them
MXPA05010681A (en) 2003-04-04 2005-12-15 Diversa Corp Pectate lyases, nucleic acids encoding them and methods for making and using them.
JP2007500514A (en) 2003-04-29 2007-01-18 パイオニア ハイ−ブレッド インターナショナル， インコーポレイテッド Novel glyphosate N-acetyltransferase (GAT) gene
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
AU2004254640B2 (en) 2003-07-02 2010-08-26 Bp Corporation North America Inc. Glucanases, nucleic acids encoding them and methods for making and using them
WO2005021714A2 (en) 2003-08-11 2005-03-10 Diversa Corporation Laccases, nucleic acids encoding them and methods for making and using them
WO2005123929A2 (en) 2004-06-09 2005-12-29 Pioneer Hi-Bred International, Inc. Plastid transit peptides
CN101432292B (en) 2004-06-16 2013-03-13 维莱尼姆公司 Compositions and methods for enzymatic decolorization of chlorophyll
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP2886658A1 (en) 2005-03-10 2015-06-24 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
JP5343212B2 (en) 2005-03-15 2013-11-13 ヴェレニウム コーポレイション Cellulases, nucleic acids encoding them, and methods of making and using them
US8715988B2 (en) 2005-03-28 2014-05-06 California Institute Of Technology Alkane oxidation by modified hydroxylases
WO2007092314A2 (en) 2006-02-02 2007-08-16 Verenium Corporation Esterases and related nucleic acids and methods
MY160770A (en) 2006-02-10 2017-03-15 Verenium Corp Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
PL1989302T3 (en) 2006-02-14 2019-03-29 Bp Corp North America Inc Xylanases, nucleic acids encoding them and methods for making and using them
US8043837B2 (en) 2006-03-07 2011-10-25 Cargill, Incorporated Aldolases, nucleic acids encoding them and methods for making and using them
US8546118B2 (en) 2006-03-07 2013-10-01 Verenium Corporation Aldolases, nucleic acids encoding them and methods for making and using them
WO2009020459A2 (en) 2006-08-04 2009-02-12 Verenium Corporation Glucanases, nucleic acids encoding them and methods for making and using them
US8637290B2 (en) 2006-09-21 2014-01-28 Dsm Ip Assets B.V. Phospholipases, nucleic acids encoding them and methods for making and using them
CN104450754B (en) 2006-09-21 2021-10-01 巴斯夫酶有限责任公司 Phytases, nucleic acids encoding them, and methods of making and using them
ES2734114T3 (en) 2006-12-21 2019-12-04 Basf Enzymes Llc Amylases and glucoamylases, nucleic acids that encode them and methods to form and use them
JP2010516296A (en) 2007-01-30 2010-05-20 ヴェレニウム コーポレイション Enzymes for treating lignocellulosic substances, nucleic acids encoding the same and methods for producing and using the same
DK2708602T3 (en) 2007-10-03 2019-06-03 Bp Corp North America Inc Xylanases, nucleic acids encoding them and methods of making and using them
CN103172750B (en) 2007-11-01 2014-12-10 安斯泰来制药有限公司 Immunosuppressive polypeptides and nucleic acids
US8709772B2 (en) 2008-01-03 2014-04-29 Verenium Corporation Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them
DK2238261T3 (en) 2008-01-03 2014-02-10 Verenium Corp Isomerases, nucleic acids encoding them and processes for their preparation and use
BRPI0909611B8 (en) 2008-05-23 2022-12-06 Pioneer Hi Bred Int METHOD OF INCREASE THE TOTAL FATTY ACID CONTENT OF AN OILSEED CELL, RECOMBINANT NUCLEIC ACID, CONSTRUCTION OF RECOMBINANT DNA AND METHOD OF PRODUCTION OF AN OILSEED
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
CN102227503B (en) 2008-09-26 2015-10-21 托卡根公司 recombinant vector
HUE030948T2 (en) 2009-05-21 2017-06-28 Basf Enzymes Llc Phytases, nucleic acids encoding them and methods for making and using them
CN102549009A (en) 2009-08-20 2012-07-04 先锋国际良种公司 Functional expression of shuffled yeast nitrate transporter (YNT1) in maize to improve nitrate uptake under low nitrate environment
UA109884C2 (en) 2009-10-16 2015-10-26 A POLYPEPTIDE THAT HAS THE ACTIVITY OF THE PHOSPHATIDYLINOSYTOL-SPECIFIC PHOSPHOLIPASE C, NUCLEIC ACID, AND METHOD OF METHOD
WO2011082304A1 (en) 2009-12-31 2011-07-07 Pioneer Hi-Bred International, Inc. Engineering plant resistance to diseases caused by pathogens
BR112013003221A2 (en) 2010-08-13 2019-09-24 Pioneer Hi Bred Int chimeric polynucleotide, nucleic acid construct, cell, plant, plant explant, transgenic seed, chimeric polypeptide, method of directing a polypeptide of interest to a chloroplast, expression cassette, plant cell, isolated polypeptide
CN104411823A (en) 2012-05-04 2015-03-11 纳幕尔杜邦公司 Compositions and methods comprising sequences having meganuclease activity
US20160053277A1 (en) 2013-03-14 2016-02-25 Pioneer Hi-Bred International, Inc. Compositions Having Dicamba Decarboxylase Activity and Methods of Use
CA2904537A1 (en) 2013-03-14 2014-09-25 Pioneer Hi-Bred International, Inc. Compositions having dicamba decarboxylase activity and methods of use
CN105473605A (en) 2013-03-15 2016-04-06 先锋国际良种公司 Phi-4 polypeptides and methods for their use
CA2920339C (en) 2013-08-16 2023-10-24 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
MX359027B (en) 2013-09-13 2018-09-12 Pioneer Hi Bred Int INSECTICIDAL PROTEINS and METHODS FOR THEIR USE.
US10227608B2 (en) 2014-02-07 2019-03-12 Pioneer Hi-Bred International, Inc. Insecticidal proteins from plants and methods for their use
BR112016018103B1 (en) 2014-02-07 2024-01-16 E.I. Du Pont De Nemours And Company POLYPEPTIDE AND ITS USE, POLYNUCLEOTIDE, COMPOSITION, FUSION PROTEIN, METHOD FOR CONTROLING A POPULATION, METHOD FOR INHIBITING GROWTH, METHOD FOR CONTROLING INFESTATION, METHOD FOR OBTAINING A PLANT OR PLANT CELL, CONSTRUCTION
US10098943B2 (en) * 2014-09-11 2018-10-16 Vlp Therapeutics, Llc Flavivirus virus like particle
CN107108705B (en) 2014-10-16 2021-05-25 先锋国际良种公司 Insecticidal protein and method of use
RU2740312C2 (en) 2015-01-15 2021-01-13 Пайониэ Хай-Бред Интернешнл, Инк. Insecticidal proteins and methods for using them
CN107529763B (en) 2015-03-11 2021-08-20 先锋国际良种公司 Insecticidal combination of PIP-72 and method of use
CN116333064A (en) 2015-05-19 2023-06-27 先锋国际良种公司 Insecticidal proteins and methods of use thereof
BR122023016256B8 (en) 2015-08-06 2024-04-30 Du Pont Recombinant insecticidal polypeptide, recombinant polynucleotide, dna construct, method of obtaining a transgenic plant or transgenic plant cell, composition, fusion protein, method for controlling a pest, method for inhibiting growth or for exterminating a pest population and use of polypeptide
WO2017105987A1 (en) 2015-12-18 2017-06-22 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
EP3960863B1 (en) 2016-05-04 2024-11-13 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
WO2017220499A1 (en) 2016-06-20 2017-12-28 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
CN109788735A (en) 2016-07-01 2019-05-21 先锋国际良种公司 Insecticidal protein and its application method from plant
CA3038806A1 (en) 2016-11-01 2018-05-11 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
WO2018111551A1 (en) 2016-12-14 2018-06-21 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
EP3558004A1 (en) 2016-12-22 2019-10-30 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
WO2018148001A1 (en) 2017-02-08 2018-08-16 Pioneer Hi-Bred International Inc Insecticidal combinations of plant derived insecticidal proteins and methods for their use
US11555203B2 (en) 2017-05-11 2023-01-17 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
WO2019178038A1 (en) 2018-03-14 2019-09-19 Pioneer Hi-Bred International, Inc. Insecticidal proteins from plants and methods for their use
CN115850420A (en) 2018-03-14 2023-03-28 先锋国际良种公司 Insecticidal proteins from plants and methods of use thereof
WO2020198731A2 (en) 2019-03-28 2020-10-01 Danisco Us Inc Engineered antibodies
WO2021142393A1 (en) 2020-01-10 2021-07-15 The Regents Of The University Of California Biosynthetic platform for the production of olivetolic avid and analogues of olivetolic acid
BR112022027035A2 (en) 2020-07-14 2023-04-11 Pioneer Hi Bred Int INSECTICIDAL PROTEINS AND METHODS FOR THE USE OF THEM

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016027A1 (en) * 1993-12-06 1995-06-15 Bioinvent International Ab Method of selecting specific bacteriophages
WO1996011279A2 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
WO1997007128A1 (en) * 1995-08-21 1997-02-27 Duke University A method to increase the density of antigen on antigen presenting cells
WO1997020078A1 (en) * 1995-11-30 1997-06-05 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
WO1997032987A1 (en) * 1996-03-08 1997-09-12 University Of Toronto Methods and nucleic immunogenic compositions encoding antigens and co-stimulatory molecules for immunization
WO1997035957A1 (en) * 1996-03-25 1997-10-02 Maxygen, Inc. Evolving cellular dna uptake by recursive sequence recombination

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882278A (en) * 1983-04-29 1989-11-21 President And Fellows Of Harvard College Non-toxinogenic vibrio cholerae mutants
IL96475A0 (en) * 1989-11-29 1991-08-16 Innovative Tech Center Chimeric proteins
AU6707194A (en) * 1993-04-19 1994-11-08 Medisorb Technologies International L.P. Encapsulation of nucleic acids with conjugates that facilitate and target cellular uptake and gene expression
SG54115A1 (en) * 1993-04-27 1998-11-16 Gerber Scient Products Inc Thermal printing apparatus with improved power supply
WO1994026787A1 (en) * 1993-05-07 1994-11-24 The Board Of Trustees Of The Leland Stanford Junior University Method for generating cell type specific phage antibody libraries
WO1996013250A1 (en) * 1994-10-27 1996-05-09 Amgem Inc. Compositions for increased bioavailability of orally delivered therapeutic agents
WO1996023882A1 (en) * 1995-01-31 1996-08-08 The Rockefeller University IDENTIFICATION OF DEC, (DENTRITIC AND EPITHELIAL CELLS, 205 kDa), A RECEPTOR WITH C-TYPE LECTIN DOMAINS, NUCLEIC ACIDS ENCODING DEC, AND USES THEREOF
CZ92998A3 (en) * 1995-09-28 1998-09-16 University Of Pittsburgh Of The Commonwealth System Of Higher Education A method of stimulating a cell-mediated immune response by targeted immunization with a particle-bound gene material
US6489145B1 (en) * 1996-07-09 2002-12-03 Diversa Corporation Method of DNA shuffling

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016027A1 (en) * 1993-12-06 1995-06-15 Bioinvent International Ab Method of selecting specific bacteriophages
WO1996011279A2 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
WO1997007128A1 (en) * 1995-08-21 1997-02-27 Duke University A method to increase the density of antigen on antigen presenting cells
WO1997020078A1 (en) * 1995-11-30 1997-06-05 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
WO1997032987A1 (en) * 1996-03-08 1997-09-12 University Of Toronto Methods and nucleic immunogenic compositions encoding antigens and co-stimulatory molecules for immunization
WO1997035957A1 (en) * 1996-03-25 1997-10-02 Maxygen, Inc. Evolving cellular dna uptake by recursive sequence recombination

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
BENHAM A.M. & NEEFJES J.J.: "Proteasome activity limits the assembly f MHC class I molecules after IFN-gamma stimulation.", J. IMMUNOL., vol. 159, no. 2, 15 December 1997 (1997-12-15), pages 5896 - 5904, XP002117254 *
CONRY R M ET AL: "SELECTED STRATEGIES TO AUGMENT POLYNUCLEOTIDE IMMUNIZATION", GENE THERAPY, vol. 3, no. 1, 1 January 1996 (1996-01-01), pages 67 - 74, XP002035090, ISSN: 0969-7128 *
DAVIS H L ET AL: "DNA-based immunization against hepatitis B surface antigen (HBsAg) in normal and HBsAg-transgenic mice", VACCINE, vol. 15, no. 8, 1 June 1997 (1997-06-01), pages 849-852, XP004075668, ISSN: 0264-410X *
HOURVITZ A. ET AL.: "Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens: a preliminary report", J. VIRAL HEPATITIS, vol. 3, 1996, pages 37 - 42, XP002117256 *
IRVINE K R ET AL: "CYTOKINE ENHANCEMENT OF DNA IMMUNIZATION LEADS TO EFFECTIVE TREATMENT OF ESTABLISHED PULMONARY METASTASES", JOURNAL OF IMMUNOLOGY, vol. 156, 1 January 1996 (1996-01-01), pages 238 - 245, XP002030631, ISSN: 0022-1767 *
KLINMAN D.M. ET AL.: "Contribution of CpG motifs to the immunogenicity of DNA vaccines", J. IMMUNOLOGY, vol. 158, 1997, pages 3635 - 3639, XP002108454 *
KRIEGER M ET AL: "MOLECULAR FLYPAPER, ATHEROSCLEROSIS, AND HOST DEFENSE: STRUCTURE AND FUNCTION OF THE MACROPHAGE SCAVENGER RECEPTOR", COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, vol. 57, 1 January 1992 (1992-01-01), pages 605 - 609, XP000561876 *
MARCO DI A ET AL: "AGONISTIC AND ANTAGONISTIC VARIANTS OF CILIARY NEUROTROPHIC FACTOR (CNTF) REVEAL FUNCTIONAL DIFFERENCES BETWEEN MEMBRANE-BOUND AND SOLUBLE CNTF ALPHA-RECEPTOR", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 37, 12 September 1997 (1997-09-12), pages 23069 - 23075, XP002069814, ISSN: 0021-9258 *
PATTEN P A ET AL: "APPLICATIONS OF DNA SHUFFLING TO PHARMACEUTICALS AND VACCINES", CURRENT OPINION IN BIOTECHNOLOGY, vol. 8, 1997, pages 724 - 733, XP002916609, ISSN: 0958-1669 *
SAGGIO I ET AL: "CNTF VARIANTS WITH INCREASED BIOLOGICAL POTENCY AND RECEPTOR SELECTIVITY DEFINE A FUNCTIONAL SITE OF RECEPTOR INTERACTION", EMBO JOURNAL, vol. 14, no. 13, 1 January 1995 (1995-01-01), pages 3045 - 3054, XP002056939, ISSN: 0261-4189 *
SHEU S.Y. & LO S.J.: "Deletion or alteration of hydrophobic amino acids at the third transmembrane domains of Hepatitis B surface antigen enhances its production in Escherichia coli.", GENE, vol. 160, no. 2, 28 July 1995 (1995-07-28), pages 179 - 184, XP002117290 *
SHOUVAL D. ET AL.: "Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines", VACCINE, vol. 12, no. 15, November 1994 (1994-11-01), pages 1453 - 1459, XP002117255 *
XIANG Z ET AL: "MANIPULATION OF THE IMMUNE RESP0NSE TO A PLASMID-ENCODED VIRAL ANTIGEN BY COINOCULATION WITH PLASMIDS EXPRESSING CYTOKINES", IMMUNITY, vol. 2, no. 2, 1 February 1995 (1995-02-01), pages 129 - 135, XP000670098, ISSN: 1074-7613 *
ZOU J.J. ET AL.: "Structure-function analysis of the p35 subunit of mouse interleukin 12", J. BIOL.CHEM., vol. 270, no. 11, 17 March 1995 (1995-03-17), pages 5864 - 5871, XP002117289 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629170B2 (en) 1997-01-17 2009-12-08 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US6821957B2 (en) 1997-05-20 2004-11-23 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US7153655B2 (en) 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US7421347B2 (en) 1999-01-19 2008-09-02 Maxygen, Inc. Identifying oligonucleotides for in vitro recombination
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US7058515B1 (en) 1999-01-19 2006-06-06 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US7620502B2 (en) 1999-01-19 2009-11-17 Maxygen, Inc. Methods for identifying sets of oligonucleotides for use in an in vitro recombination procedure
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US7462469B2 (en) 2000-01-11 2008-12-09 Maxygen, Inc. Integrated system for diversity generation and screening
US7282334B2 (en) 2000-12-12 2007-10-16 Alligator Bioscience, Ab Method for in vitro molecular evolution of protein function
US7563578B2 (en) 2000-12-12 2009-07-21 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US7262012B2 (en) 2002-05-17 2007-08-28 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populations
US9512382B2 (en) 2009-10-16 2016-12-06 Bunge Global Innovation, Llc Oil degumming methods

Also Published As

Publication number Publication date
WO1999041369A3 (en) 1999-09-23
CA2320431A1 (en) 1999-08-19
JP2002503461A (en) 2002-02-05
WO1999041402A3 (en) 1999-11-11
WO1999041368A2 (en) 1999-08-19
EP1053312A2 (en) 2000-11-22
WO1999041369A2 (en) 1999-08-19
MXPA00007891A (en) 2002-09-18
AU2674299A (en) 1999-08-30
CA2320960A1 (en) 1999-08-19
MXPA00007889A (en) 2002-09-18
WO1999041402A2 (en) 1999-08-19
EP1053343A2 (en) 2000-11-22
MXPA00007893A (en) 2002-10-23
AU3291099A (en) 1999-08-30
AU2674199A (en) 1999-08-30
JP2002507392A (en) 2002-03-12
CA2320626A1 (en) 1999-08-19
EP1056842A2 (en) 2000-12-06
JP2002503478A (en) 2002-02-05

Similar Documents

Publication Publication Date Title
WO1999041368A3 (en) Optimization of immunomodulatory properties of genetic vaccines
WO2004075829A3 (en) Adjuvanted influenza vaccine
MY125202A (en) Vaccine
ATE454163T1 (en) BACTERIAL VACCINES CONTAINING AUXOTROPHIC ATTENUATE LISTERIA STRAINS WHICH EXPRESS HETEROLOGUE ANTIGENS
WO2004006837A3 (en) Mesothelin vaccines and model systems
AU2002355677A1 (en) Antigenic polypeptides
IL211367A0 (en) An antibody, a fragment thereof, a method of preparing the same and a use of the antibody
WO1999006544A8 (en) Membrane-bound cytokine compositions and methods of modulating an immune response using same
DE69929444D1 (en) CPG COMPOSITIONS, SAPONIN ADJUVANTIES, AND METHOD OF USE THEREOF
WO1999036544A3 (en) Neisseria meningitidis antigens
DE60335010D1 (en) IMMUNOSTIMULATORY COMPOSITIONS AND METHOD FOR STIMULATING AN IMMUNE RESPONSE
WO1997009428A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
NO20001768D0 (en) Virus encapsulation vaccine, method of preparation and use thereof
AU2002365508A1 (en) Apparatus and method for modification of magnetically immobilized biomolecules
WO1999042076A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
AU2741295A (en) Method for preparing an influenza virus, antigens obtained and applications thereof
CY1107950T1 (en) NAVIGATION VACCINE COMPOSITIONS AND METHODS
WO2002062296A3 (en) Methods and compositions useful for stimulating an immune response
WO2004005476A3 (en) Nucleic acid compositions for stimulating immune responses
WO2003051288A3 (en) Mycobacterial vaccine
WO2002024739A3 (en) Spas-1 cancer antigen
ZA200104189B (en) Method to produce inactivated w/o emulsion adjuvated vaccines.
EP1518927A3 (en) Optimization of immunomodulatory properties of genetic vaccines
WO1993017115A3 (en) Dysentery vaccine stimulating an immune response against shigatoxin, plasmids and host strains for it
WO2003006055A8 (en) Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its b subunit

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2320960

Country of ref document: CA

Ref country code: CA

Ref document number: 2320960

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 2000 531549

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/007889

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 26741/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999906948

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999906948

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999906948

Country of ref document: EP